MIF tautomerase inhibitor potency of α,β-unsaturated cyclic ketones

International Immunopharmacology

Volumn 7, Issue 13, 2007, Pages 1741-1746

  Garai, János ^a   Molnár, Valéria ^a   Eros, Dániel ^b   Orfi, László ^c   Lóránd, Tamás ^d  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Vichem Chemie Ltd   (Hungary)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d UNIVERSITY OF PÉCS   (Hungary)

Author keywords

, unsaturated ketone; Curcumin; Inflammation; Macrophage migration inhibitory factor; MIF; Tautomerase

Indexed keywords

2,5 DIBENZYLIDENECYCLOPENTANONE; ANTIINFLAMMATORY AGENT; CYTOKINE RECEPTOR ANTAGONIST; KETONE DERIVATIVE; MACROPHAGE MIGRATION INHIBITION FACTOR; MACROPHAGE MIGRATION INHIBITORY FACTOR INHIBITOR; TAUTOMERASE; UNCLASSIFIED DRUG;

ARTICLE; DRUG INHIBITION; DRUG SYNTHESIS; ENZYME INHIBITION; IC 50; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

CURCUMIN; ENZYME INHIBITORS; HUMANS; INTRAMOLECULAR OXIDOREDUCTASES; KETONES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35848940072     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2007.09.014     Document Type: Article

References (28)

1. Bloom B.R., and Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 153 (1966) 80-82
2. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci U S A 56 (1966) 72-77
3. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 365 (1993) 756-759
4. Mitchell R.A., Metz C.N., Peng T., and Bucala R. Sustained mitogen activated protein kinase (MAPK) and cytoplasmic phospholipase A2 activation by macrophage migration inhibitory factor (MIF). Regulatory role in cell proliferation and glucocorticoid action. J Biol Chem 274 (1999) 18100-18106
5. Rosengren E., Bucala R., Aman P., Jacobsson L., Odh G., Metz C.N., et al. The immunoregulatory mediator macrophage migration inhibitory factor (MIF) catalyzes a tautomerization reaction. Mol Med 2 (1996) 143-149
6. Rosengren E., Aman P., Thelin S., Hansson C., Ahlfors S., Bjork P., et al. The macrophage migration inhibitory factor MIF is a phenylpyruvate tautomerase. FEBS Lett 417 (1997) 85-88
7. Kleemann R., Kapurniotu A., Frank R.W., Gessner A., Mischke R., Flieger O., et al. Disulfide analysis reveals a role for macrophage migration inhibitory factor (MIF) as thiol-protein oxidoreductase. J Mol Biol 280 (1998) 85-102
8. Nishihira J., Ishibashi T., Fukushima T., Sun B., Sato Y., and Todo S. Macrophage migration inhibitory factor (MIF): its potential role in tumor growth and tumor-associated angiogenesis. Ann NY Acad Sci 995 (2003) 171-182
9. Calandra T., Echtenacher B., Roy D.L., Pugin J., Metz C.N., Hultner L., et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat Med 6 (2000) 164-170
10. Iwaki T., Sugimura M., Nishihira J., Matsuura T., Kobayashi T., and Kanayama N. Recombinant adenovirus vector bearing antisense macrophage migration inhibitory factor cDNA prevents acute lipopolysaccharide-induced liver failure in mice. Lab Invest 83 (2003) 561-570
11. Dios A., Mitchell R.A., Aljabari B., Lubetsky J., O'Connor K., Liao H., et al. Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. J Med Chem 45 (2002) 2410-2416
12. Orita M., Yamamoto S., Katayama N., and Fujita S. Macrophage migration inhibitory factor and the discovery of tautomerase inhibitors. Curr Pharm Des 8 (2002) 1297-1317
13. Senter P.D., Al-Abed Y., Metz C.N., Benigni F., Mitchell R.A., Chesney J., et al. Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites. Proc Natl Acad Sci U S A 99 (2002) 144-149
14. Molnar V., and Garai J. Plant-derived anti-inflammatory compounds affect MIF tautomerase activity. Int Immunopharmacol 5 (2005) 849-856
15. Duvoix A., Blasius R., Delhalle S., Schnekenburger M., Morceau F., Henry E., et al. Chemopreventive and therapeutic effects of curcumin. Cancer Lett 223 (2005) 181-190
16. Lorand T., Kocsis B., Sohar P., Nagy G., Kispal G., Krane H.G., et al. Synthesis and antibacterial study of Mannich ketones. Eur J Med Chem Chim Ther 36 (2001) 705-718
17. Taylor A.B., Johnson Jr. W.H., Czerwinski R.M., Li H.-S., Hackert M.L., and Whitman C.P. Crystal structure of macrophage migration inhibitory factor complexed with (E)-2-fluoro-p-hydroxycinnamate at 1.8 A resolution: implications for enzymatic catalysis and inhibition. Biochemistry 38 (1999) 7444-7452
18. Garai J., and Adlercreutz H. Estrogen-inducible uterine flavonoid binding sites: is it time to reconsider?. J Steroid Biochem 88 (2004) 377-381
19. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) fan enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
20. Garai J., Lorand T., and Molnar V. Ketone bodies affect the enzymatic activity of macrophage migration inhibitory factor. Life Sci 77 (2005) 1375-1380
21. Orita M., Yamamoto S., Katayama N., Aoki M., Takayama K., Yamagiwa Y., et al. Coumarin and chromen-4-one analogues as tautomerase inhibitors of macrophage migration inhibitory factor: discovery and X-ray crystallography. J Med Chem 44 (2001) 540-547
22. Banerjee M., Tripathi L.M., Srivastava V.L.M., Puri A., and Shukla R. Modulation of inflammatory mediators by ibuprofen and curcumin treatment during chronic inflammation in rat. Immunopharmacol Immunot 25 (2003) 213-224
23. Gafner S., Lee S.K., Cuendet M., Barthélémy S., Vergnes L., Labidalle S., et al. Biologic evaluation of curcumin and structural derivatives in cancer chemoprevention model systems. Phytochemistry 65 (2004) 2849-2859
24. Markaverich B.M., Schauweker T.H., Gregory R.R., Varma M., Kitrell F.S., Medina D., et al. Nuclear type II site and malignant cell proliferation: inhibition by 2,6-bisbenzylidene-cyclohexanones. Cancer Res 52 (1992) 2482-2488
25. Dimmock, Padmanilayam M.P., Zello G.A., Nienaber K.H., Allen T.M., Santos C.L., et al. Cytotoxic analogues of 2,6-bis(arylidene)cyclohexanones. Eur J Med Chem 38 (2003) 169-177
26. Verma S.P., Salamone E., and Goldin B. Curcumin and genistein, plant natural products, show synergistic inhibitory effects on the growth of human breast cancer MCF-7 cells induced by estrogenic pesticides. Biochem Biophys Res Commun 233 (1997) 692-696
27. Breithofer A., Graumann K., Scicchitano M.S., Karathanasis S.K., Butt T.R., and Jungbauer A. Regulation of human estrogen receptor by phytoestrogens in yeast and human cells. J Steroid Biochem Mol Biol 67 (1998) 421-429
28. Schwartz-Mittelman A., Baruch A., Neufeld T., Buchner V., and Rishpon J. Electrochemical detection of xenoestrogenic and antiestrogenic compounds using a yeast two-hybrid-17-beta-estradiol system. Bioelectrochemistry 65 (2005) 149-156